Photodynamic Therapy in Primary Breast Cancer

Banerjee, S.; Sheikh, Soha El; Malhotra, Aseem; Mosse, Charles A.; Parker, Sweta; Williams, Norman; MacRobert, Alexander J.; Hamoudi, Rifat; Bown, Stephen G.; Keshtgar, M.

doi:10.3390/jcm9020483

Cited by 77 publications

(52 citation statements)

References 29 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depending on the type of tumor, different PDT approaches have been successfully applied. Very recently, the first reported clinical trial was conducted to evaluate the performance of PDT in the treatment of primary breast cancer in humans [ 145 ]. In this trial, verteporfin was used as a photosensitizer at a concentration of 0.4 mg/Kg.…”

Section: Photodynamic Therapymentioning

confidence: 99%

Exploring the Applications of the Photoprotective Properties of Anthocyanins in Biological Systems

Oliveira

Correia

Pereira

et al. 2020

IJMS

View full text Add to dashboard Cite

Due to their physical and chemical characteristics, anthocyanins are amongst the most versatile groups of natural compounds. Such unique signature makes these compounds a focus in several different areas of research. Anthocyanins have well been reported as bioactive compounds in a myriad of health disorders such as cardiovascular diseases, cancer, and obesity, among others, due to their anti-inflammatory, antioxidant, anti-diabetic, anti-bacterial, and anti-proliferative capacities. Such a vast number of action mechanisms may be also due to the number of structurally different anthocyanins plus their related derivatives. In this review, we highlight the recent advances on the potential use of anthocyanins in biological systems with particular focus on their photoprotective properties. Topics such as skin aging and eye degenerative diseases, highly influenced by light, and the action of anthocyanins against such damages will be discussed. Photodynamic Therapy and the potential role of anthocyanins as novel photosensitizers will be also a central theme of this review.

show abstract

Section: Photodynamic Therapymentioning

confidence: 99%

Exploring the Applications of the Photoprotective Properties of Anthocyanins in Biological Systems

Oliveira

Correia

Pereira

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Photodynamic therapy (PDT) has been employed in the clinic for treatment of a range of cancers ( e.g. skin, lung, bladder, head and neck, and very recently primary breast cancer [ 18 ] and non-oncological disorders ( e.g. antimicrobial PDT, age-related macular degeneration) [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

Deken

Kijanka

Hernández

et al. 2020

Journal of Controlled Release

View full text Add to dashboard Cite

Rationale A substantial number of breast cancer patients with an overexpression of the human epidermal growth factor receptor 2 (HER2) have residual disease after neoadjuvant therapy or become resistant to trastuzumab. Photodynamic therapy (PDT) using nanobodies targeted to HER2 is a promising treatment option for these patients. Here we investigate the in vitro and in vivo antitumor efficacy of HER2-targeted nanobody-photosensitizer (PS) conjugate PDT. Methods Nanobodies targeting HER2 were obtained from phage display selections. Monovalent nanobodies were engineered into a biparatopic construct. The specificity of selected nanobodies was tested in immunofluorescence assays and their affinity was evaluated in binding studies, both performed in a panel of breast cancer cells varying in HER2 expression levels. The selected HER2-targeted nanobodies 1D5 and 1D5-18A12 were conjugated to the photosensitizer IRDye700DX and tested in in vitro PDT assays. Mice bearing orthotopic HCC1954 trastuzumab-resistant tumors with high HER2 expression or MCF-7 tumors with low HER2 expression were intravenously injected with nanobody-PS conjugates. Quantitative fluorescence spectroscopy was performed for the determination of the local pharmacokinetics of the fluorescence conjugates. After nanobody-PS administration, tumors were illuminated to a fluence of 100 J∙cm -2 , with a fluence rate of 50 mW∙cm -2 , and thereafter tumor growth was measured with a follow-up until 30 days. Results The selected nanobodies remained functional after conjugation to the PS, binding specifically and with high affinity to HER2-positive cells. Both nanobody-PS conjugates potently and selectively induced cell death of HER2 overexpressing cells, either sensitive or resistant to trastuzumab, with low nanomolar LD 50 values. In vivo , quantitative fluorescence spectroscopy showed specific accumulation of nanobody-PS conjugates in HCC1954 tumors and indicated 2 h post injection as the most suitable time point to apply light. Nanobody-targeted PDT with 1D5-PS and 1D5-18A12-PS induced significant tumor regression of trastuzumab-resistant high HER2 expressing tumors, whereas in low HER2 expressing tumors only a slight growth delay was observed. Conclusion Nanobody-PS conjugates accumulated selectively in vivo and their fluorescence could be detected through optical imaging. Upon illumination, they selectively induced significant tumor regression of HER2 overexpressing tumors with a single treatment session. Nanobody-targeted PDT is therefore suggested as a new additional treatment for HER2-positive breast cancer, particularly of interest for trastuzumab-resistant HER2-positive breast cancer. Further studies are now needed to assess the value of t...

show abstract

“…Fifty patients were followed up for 8 months, with the photodynamic effect detected by PDT. The laser fiber inserted by percutaneous positioning needle can directly transmit light energy to the main body of the tumor, which has little impact on the skin and surrounding tissues (Banerjee et al, 2020). In the future, it may become a new possibility for the treatment of breast tumor that has no response to neoadjuvant therapy or slight response.…”

Section: The Role Of Verteporfin As a Photosensitizer In Solid Tumorsmentioning

confidence: 99%

The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor

Wei

2020

Front. Pharmacol.

View full text Add to dashboard Cite

Verteporfin (VP) has long been clinically used to treat age-related macular degeneration (AMD) through photodynamic therapy (PDT). Recent studies have reported a significant anti-tumor effect of VP as well. Yes-associated protein (YAP) is a pro-tumorigenic factor that is aberrantly expressed in various cancers and is a central effector of the Hippo signaling pathway that regulates organ size and tumorigenesis. VP can inhibit YAP without photoactivation, along with suppressing autophagy, and downregulating germinal center kinase-like kinase (GLK) and STE20/SPS1-related proline/alanine-rich kinase (SPAK). In addition, VP can induce mitochondrial damage and increase the production of reactive oxygen species (ROS) upon photoactivation, and is an effective photosensitizer (PS) in anti-tumor PDT. We have reviewed the direct and adjuvant therapeutic action of VP as a PS, and its YAP/TEA domain (TEAD)-dependent and independent pharmacological effects in the absence of light activation against cancer cells and solid tumors. Based on the present evidence, VP may be repositioned as a promising anti-cancer chemotherapeutic and adjuvant drug.

show abstract

Photodynamic Therapy in Primary Breast Cancer

Cited by 77 publications

References 29 publications

Exploring the Applications of the Photoprotective Properties of Anthocyanins in Biological Systems

Exploring the Applications of the Photoprotective Properties of Anthocyanins in Biological Systems

Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor

Contact Info

Product

Resources

About